Literature DB >> 30031937

Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease.

Areej El-Jawahri1, Joseph Pidala2, Nandita Khera3, William A Wood4, Mukta Arora5, Paul A Carpenter6, Jeanne Palmer7, Mary E Flowers6, Madan Jagasia8, Yi-Bin Chen9, Stephanie J Lee6.   

Abstract

Data on psychological distress and its association with clinical outcomes in patients with chronic graft-versus-host-disease (GVHD) are lacking. We used data of patients with chronic GVHD (N = 482) from the Chronic GVHD Consortium, a prospective observational multicenter cohort. We examined the relationship between self-reported depression or anxiety symptoms (measured by the Lee Symptom Scale) and patients' quality of life (QOL; measured by the Functional Assessment of Cancer Therapy-General [FACT-G] and the Physical Component Scale [PCS] of the 36-item Short-Form Health Survey), physical functioning (measured by the Human Activity Profile), functional status (measured by the 2-minute walk test), and overall survival (OS). Overall, 19.3% of patients (93/481) reported being moderately to extremely bothered by depression, and 22.8% (110/482) reported being moderately to extremely bothered by anxiety, with 14.1% (68/482) of those reporting being bothered by both. In multivariable models adjusted for clinical covariates, patients with self-reported depression had worse QOL (FACT-G: β = -23.09, P < .001; PCS: β = -4.94, P < .001), physical functioning (β = -8.31, P < .001), functional status (β = -37.21, P = .025), and lower OS (hazard ratio, 1.62; P = .020) compared with those with no depression symptoms. Patients who reported anxiety also had lower QOL (FACT-G: β = -19.47, P < .001; PCS: β = -3.91, P < .001), physical functioning (β = -6.69, P < .001), and functional status (β = -32.42, P = .036) but no difference in OS. Patients with chronic GVHD who report depression or anxiety symptoms have significantly compromised QOL and physical functioning. Self-reported depression is associated with lower OS. Patients with chronic GVHD and self-reported depression or anxiety represent a highly vulnerable population at risk for poor clinical outcomes and substantial morbidity from their illness.
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Chronic graft-versus-host disease; Depression; Psychological distress; Transplant survivors

Mesh:

Year:  2018        PMID: 30031937     DOI: 10.1016/j.bbmt.2018.07.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

Review 1.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

Review 2.  What else do I need to worry about when treating graft-versus-host disease?

Authors:  Areej El-Jawahri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology.

Authors:  Rachel E Reingold; Jilliana Monnier; Marco Ardigò; Joseph R Stoll; Maria C Pena; Japbani K Nanda; Stephen W Dusza; Josel D Ruiz; Lisa Flynn; Antara Afrin; Elizabeth G Klein; Susan E Prockop; Melissa P Pulitzer; Doris M Ponce; Alina Markova; Manu Jain
Journal:  Transplant Cell Ther       Date:  2021-09-24

4.  Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

Authors:  Geoffrey D E Cuvelier; Eneida R Nemecek; Justin T Wahlstrom; Carrie L Kitko; Victor A Lewis; Tal Schechter; David A Jacobsohn; Andrew C Harris; Michael A Pulsipher; Henrique Bittencourt; Sung Won Choi; Emi H Caywood; Kimberly A Kasow; Monica Bhatia; Benjamin R Oshrine; Allyson Flower; Sonali Chaudhury; Donald Coulter; Joseph H Chewning; Michael Joyce; Süreyya Savaşan; Anna B Pawlowska; Gail C Megason; David Mitchell; Alexandra C Cheerva; Anita Lawitschka; Lori J West; Bo Pan; Yazid N Al Hamarneh; Anat Halevy; Kirk R Schultz
Journal:  Blood       Date:  2019-05-01       Impact factor: 25.476

5.  Important factors associated with sick leave after allogeneic haematopoietic stem cell transplantation-a 1-year prospective study.

Authors:  Linda Eriksson; Agneta Wennman-Larsen; Karin Bergkvist; Per Ljungman; Jeanette Winterling
Journal:  J Cancer Surviv       Date:  2021-01-08       Impact factor: 4.442

6.  Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease.

Authors:  Sencer Goklemez; Leorey N Saligan; Filip Pirsl; Noa G Holtzman; Alen Ostojic; Seth M Steinberg; Frances T Hakim; Jeremy J Rose; Zhigang Kang; Yunkai Yu; Liang Cao; Sandra A Mitchell; Annie Im; Steven Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2021-08-25       Impact factor: 5.483

Review 7.  Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.

Authors:  Freya Wenzel; Anne Pralong; Udo Holtick; Christoph Scheid; Marco Herling; Steffen T Simon
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 8.  Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.

Authors:  Daniel Wolff; Giancarlo Fatobene; Vanderson Rocha; Nicolaus Kröger; Mary E Flowers
Journal:  Bone Marrow Transplant       Date:  2021-07-03       Impact factor: 5.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.